# Cizzle Bio appoints iGenomeDX to launch CIZ1B biomarker test in USA

- Link: https://www.directorstalkinterviews.com/cizzle-bio-appoints-igenomedx-to-launch-ciz1b-biomarker-test-in-usa/4121188981
- Published: 2025-03-24T07:18:34+00:00
- Author: Amilia Stone

**Cizzle Biotechnology Holdings plc **(LON:CIZ), the UK based diagnostics developer
of early cancer tests, has announced that its licensing partner Cizzle Bio Inc has
appointed iGenomeDX, a specialist clinical diagnostics laboratory to launch the 
Company’s first commercial CIZ1B biomarker test in the USA. iGenomeDX is a Commission
on Office Laboratory Accreditation (COLA) accredited and Clinical Laboratory Improvement
Amendments (CLIA) certified clinical laboratory and has been establishing operating
and quality systems ahead of offering the test to clinicians for the first time.

**Key Highlights**

·    iGenoneDX appointed by BIO as first clinical diagnostics laboratory to offer
commercial CIZ1B biomarker testing.

·    This follows successful collaboration and support between Cizzle, iGenomeDX
and BIO to complete an operational and quality systems programme designed to meet
the exacting standards required in iGenomeDX’s COLA accredited, CLIA certified laboratory,
designated to validate CIZ1b as a laboratory developed test for commercial use ahead
of the launch of the CIZ1B biomarker test.

**Background**

On 21 October 2024 the Company announced an exclusive licensing and partnership 
agreement with BIO for its proprietary CIZ1B biomarker test to help detect early-
stage lung cancer, throughout the USA and Canada.  The Company has since received
payments of US$400,000 due from initial exclusivity fees and advanced royalties 
as part of guaranteed payments totalling US$2.4 million over the period ending April
2027.  The Company has now extended that agreement, as announced on 16 December 
2024, to cover the 14 Sovereign States of the Caribbean and the Cayman Islands (“
Caribbean”) triggering early payments totalling US$250,000 in July 2025 and US$250,000
in September 2025.

The appointment of iGenomeDX by BIO, a specialist clinical diagnostics laboratory,
is the next step in the Company’s plan to achieve commercial sales later this year
by providing an accredited facility to launch the CIZ1B biomarker test.  The accreditation
process involved an evaluation of a laboratory’s operations, including its testing
procedures, quality control, personnel qualifications, and compliance with regulatory
requirements.  Labs that achieve COLA accreditation demonstrate a commitment to 
maintaining high standards of accuracy, reliability, and patient safety in diagnostic
testing to ensure they meet CLIA standards and can legally operate.

The successful completion of the operational and quality systems programme is necessary
for launching a cost-effective and scalable version of the CIZ1B biomarker assay
with rigorous quality control requirements to meet expected reproducibility and 
sensitivity.  This will demonstrate the test is commercially scalable and can be
rolled out as a global solution to help reduce premature cancer deaths and improve
survival rates and quality of life for cancer patients.

> **Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:**
> “I am delighted to announce the positive progress being made by our partners Cizzle
> Bio who have appointed the first of their COLA and CLIA accredited clinical diagnostics
> laboratories to bring our CIZ1B Biomarker test for early-stage lung cancer to 
> market.  In the short time since we began our exclusive licensing partnership 
> with Cizzle Bio, they have initiated multiple ongoing partnerships with several
> National Cancer Institute (NCI) designated cancer centres throughout the United
> States, with the goal of enhancing early detection capabilities for lung cancer.
> They have strengthened their leadership team with industry and clinical expertise
> and in creating the launchpad for our CIZ1B biomarker test.  In collaboration 
> with Cizzle Bio we continue to work closely with iGenomeDX’s exceptional leadership
> and technical team to ensure a seamless transition of technology into the clinic.
> We look forward to sharing updates on their first commercially available tests
> in the near future.”

Share on:
